Clinical Trial Update: Nalirinox Neo-pancreas RAS Mut ctDNA Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Nalirinox in resectable pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Nalirinox

Snippet

Sponsor: Fundación de investigación HM | Conditions: Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: UNKNOWN